{
    "nct_id": "NCT04819373",
    "official_title": "A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment",
    "inclusion_criteria": "Inclusion Criteria\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Histologically or cytologically confirmed: Cutaneous SCC, Head and Neck SCC, Melanoma, Merkel Cell Carcinoma, NSCLC, Renal Cell Carcinoma, or Urothelial Carcinoma. Other tumor types will be allowed at Sponsor's discretion.\n2. Tumor progression on the most recent line of treatment with anti-PD-1 or anti-PD-L1 mAb as monotherapy or in combination.\n3. Eastern Cooperative Oncology Group (ECOG) score of 0 - 2\n4. At least 1 lesion with measurable disease at baseline\n5. Availability of a lesion for biopsy and consent to allow pre-treatment tumor biopsy.\n\nExclusion Criteria\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Greater than 4 lines of prior DNA-damaging chemotherapies.\n2. Uncontrolled CNS metastases.\n3. Active autoimmune disease.\n\nOther protocol defined inclusion/exclusion criteria could apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}